Lipum and NorthX Biologics enter into new strategic manufacturing alliance
Lipum AB (Publ), a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases today announces that it has entered into a manufacturing alliance with NorthX Biologics AB, a Contract Development and Manufacturing Organisation (CDMO). Under this agreement NorthX will manufacture Lipum´s lead asset, SOL-116, a humanized antibody, [...]